Follica - New Patent Published 2017 - Needling Device And Drug Applicator | HairLossTalk Forums
  1. New! Great hair recovery from a Hair Transplant: FUE With No Scar - Doganay Turkey
    Dismiss Notice
  2. Robotic Hair Transplants?! Check out these Before and After Photos - Bernstein NYC.
    Dismiss Notice
Dismiss Notice
A Natural Hairline Completely Restored by Dr. Bisanga with an FUE Hair Transplant.

Follica - New Patent Published 2017 - Needling Device And Drug Applicator

Discussion in 'New Research, Studies, and Technologies' started by Noisette, Aug 1, 2017.

Tags:
  1. Noisette

    Noisette Established Member

    Joined:
    Jan 4, 2016
    Messages:
    146
    Likes Received:
    558
    Dislikes Received:
    1
    Hey girls and guys

    I think it's the patent which was mentioned in the article called " Follica Announces Allowance for a U.S. Patent Related to its Principal Technology Platform to Treat Hair Loss ". In september 2015, Puretech Health has announced that it has received notice from the US Patent and Trademark Office of a patent allowance on its novel hair loss treatments.

    - The new patent published at the end of March 2017 is untitled " Needling device and drug applicator "

    1. In this we can read that the applicators may also be used in combination with drugs for alopecia being developed by SWITCH Biotech LLC. There is a developement of an unknown new drug (pre-clinical phase).

    2. May also be used in combination with SM04554, and KYTH105 (setipiprant) !

    Source: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017054009

    upload_2017-8-2_1-18-1.png

    01.jpg 2.jpg




    I paste some informations. Sorry for the long post :) :)

    Summary : A needling device may be used for needling of a subject's skin, and a drug applicator device may be used for applying a drug to a subject's skin. For example, a needling device may be applied to a subject's skin for hair growth applications, or may be used for wrinkle, scar, or tattoo removal. A drug applicator device may be used for multiple drug application purposes such as applying a hair growth compound to the skin of a subject.

    2. BACKGROUND OF THE INVENTION

    2.1 FIELD OF THE INVENTION

    [0002] The following description relates to a needling device for needling of a subject's skin by a user such as a physician or any user, and a fluid or drug dispensing applicator device for massaging and applying a fluid or drug to a subject's skin. In certain embodiments, the subject is in need of inducing hair growth or hair follicle neogenesis, is need of preventing hair loss, and/or is a subject as described in Section 5.5. For example, a needling device may be applied to a subject's skin for hair growth applications, or may also be used for wrinkle reduction, scar revision, hair removal, tattoo removal, and pigmentation. The fluid or drug applicator device may be used for multiple drug application purposes such as applying a hair growth compound to the skin of a subject or treatment for other dermatological conditions.

    [00010] In yet another additional aspect, a method of using a needling device and a drug applicator for stimulating hair growth includes providing a needling device including a sheath assembly having a needle array and a main unit having a motor for driving the needle array, providing a drug applicator for drug delivery and massaging including a housing, a drug delivery cartridge carried by the housing, a massage head which is mounted on the housing for massaging a subject's skin, using the needling device to perform targeted cutaneous perturbation for disrupting a layer of a human scalp, after using the needling device, using the drug applicator for applying a drug to the disrupted area of the human scalp. In a specific embodiment, the disrupted layer of the human scalp is the basal or suprabasal epidermal layer, and the drug that is applied is minoxidil or a proteasome inhibitor including lactacystin, a peptidyl aldehyde, or pentoxyfilline (PTX). In a specific embodiment, the method further comprises delivering the drug directly to the human scalp to facilitate transdermal transport. In a specific embodiment, the method further comprises massaging the drug that is delivered to the human scalp to evenly spread the drug.

    (...) the applicator is configured to stretch or massage a subject's skin while simultaneously dispensing the drug. In a specific embodiment, an amount of drug being dispensed can be controlled by controlling a number of massaging strokes per massaging cycle, a stroke distance per massaging cycle, or a profile of the dispensing mechanism. In a specific embodiment, the drug that is applied is minoxidil or a proteasome inhibitor including lactacystin, a peptidyl aldehyde, or pentoxyfilline (PTX).

    (...) In a specific embodiment, the applicator further comprises a keypad positioned on a surface of the applicator. In a specific embodiment, the applicator further comprises an LED and a control unit configured to operate the LED in response to determining that a next dose is due. In a specific embodiment, the applicator further comprises an inductive charging base configured to receive the housing for charging the applicator. In a specific embodiment, the applicator further comprises a light for illuminating a target region of the user's skin.

    (...) a cam drive which is mounted in the housing and rotates the drug delivery cartridge and the massage head for providing a massaging effect, and a controller and sensors that are configured to detect a rotation angle of the massage head to determine a dispensed dosage using the detected angle<;

    (...) [000138] In an example, density control of the number of perturbations or skin perforations per square area of the target surface is available in a low density, medium density, and high density configuration for ease and simplicity to a user. The density of needling referred to herein is determined by the number of needles 216 in contact with a subject's skin at a given time during a needling operation and per square area of the subject's skin. The density may range in value and in an example the density ranges in value from the ratio of skin perforations surface area to the total skin surface area being 1% to that ratio being 40%.

    5.1.2 ASPECTS OF THE DESCRIBED EMBODIMENTS OF THE NEEDLING

    DEVICE [000161] In an aspect, the needling devices and needling adaptors described in all embodiments above suitable to promote hair follicle neogenesis through targeted cutaneous perturbation (TCP) of the skin (e.g., the scalp). In a specific embodiment, TCP refers to integumental perturbation of one or more epidermal layers (see, e.g., Sections 5.3 and 5.4), for example, the basal and/or suprabasal epidermal layers. In a specific embodiment, the integumental perturbation performed by the needling devices and needling adaptors described herein is followed by the application of a compound (see, e.g., Section 5.6) to the skin. Without being bound by any particular theory, TCP triggers generation of new hair follicles by induction of epithelial stem cells. See, e.g., Sections 5.3 and 5.4 for a more detailed discussion of integumental perturbation and methods of using the needling devices and needling adaptors. In other examples, the needling devices and needling adaptors or interchangeable needling adaptors with needle arrays having different configurations (such as is illustrated in the example of FIGS. 18 and 24) can be used for other applications such as wrinkle reduction, scar revision, hair removal, and tattoo removal.

    (...) The needling device may also be used in combination with guides that fit over the needle array in order to direct movement through a subject's hair; for example, the guides can be similar to hair clipper attachments.

    (...) In an example, the fluid applicator is a drug applicator that is used for the application of minoxidil to a subject's scalp or for a variety of different applications using different chemicals. With respect to all embodiments of the drug or fluid applicators, it should be appreciated that any type of fluid may be used and this invention is not limited to the use of a drug.

    [000169] In one aspect, drug applicators may be used in combination with other agents or treatments that stimulate hair growth.
    In another aspect, the applicators may also be used in combination with drugs for alopecia being developed by SWITCH Biotech LLC.

    [000170] In addition, other compounds that may be used with the applicator include compounds identified by the following company and company ID, Actelion ACT- 129968 (setipiprant), Actimis AP768, Amira AM211, Amira AM461, Amgen AMG853, Array BiPharma ARRY-502, AstraZeneca AZD1981, AstraZeneca AZD8075, AstraZeneca AZD5985, Merck MK-7246, Novartis QAV680, Oxagen OC000459, Ocagen OC002417, Pulmagen ADC3680B, Shionogi S-555739, BBI-5000, SM04554, and KYTH105 (setipiprant).

    [000254] In a specific embodiment, the devices and/or mobile apps described herein are suitable to achieve one or more of the following nonlimiting examples of biological outcomes in a subject on which the devices and/or mobile apps were used: to promote generation of new hair follicles ("follicle neogenesis"); to promote formation of neogenic-like (NL) follicular structures; to promote activation (possibly by reorganization) of existing hair follicles; to promote formation of pre-exi sting-like (PEL) or pre-exi sting-like, attached (PELA) follicular structures; to promote development of hair follicles, for example, to promote the growth of terminal hair (in preference to vellus hair); to promote the branching of pre-existing hair follicles (seen as an increased number of hair shafts per pore); to increase the width of hair follicles (thereby promoting growth of an increased shaft width); to delay or prevent follicle senescence;

    [000263] The subject may have a disease or disorder of balding or hair loss (including hair thinning), such as forms of nonscarring (noncicatricial) alopecia, such as androgenetic alopecia (Androgenetic Alopecia), including male-patterned hair loss (MPHL) or female-patterned hair loss (FPHL) (e.g., thinning of the hair, i.e., diffuse hair loss in the frontal/parietal scalp), or any other form of hair loss caused by androgens, toxic alopecia, alopecia areata (including alopecia universalis), scarring (cicatricial) alopecia, pathologic alopecia (caused by, e.g., medication, trauma stress, autoimmune diseases, malnutrition, or endocrine dysfunction), trichotillomania, a form of hypotrichosis, such as congenital hypotrichosis, or lichen planopilaris, or any other condition of hair loss or balding known in the art or described infra.


     
    #1 Noisette, Aug 1, 2017
    Last edited: Aug 1, 2017
  2. Blackber

    Blackber Experienced Member

    Joined:
    Jun 17, 2014
    Messages:
    565
    Likes Received:
    490
    Dislikes Received:
    4
    Great find as always.
     
  3. InBeforeTheCure

    InBeforeTheCure Established Member My Regimen

    Joined:
    Oct 5, 2015
    Messages:
    265
    Likes Received:
    416
    Dislikes Received:
    1
    My Regimen:
    My Regimen
    My Regimen
    All CRTH2 antagonists except for SM04554.
     
  4. occulus

    occulus Experienced Member

    Joined:
    Feb 22, 2016
    Messages:
    574
    Likes Received:
    353
    Dislikes Received:
    61
    Unless Switch is significantly further along than they claim, Follica will probably launch with minoxidil only, then add to their regimen as novel drugs are approved. At the same time, they list about 100 potential "compounds," and some of them are - like minoxidil - commercially available, so who knows. That is pretty disappointing if that's the case, but it makes sense. If that is indeed their plan, there is no reason to believe they won't launch by the end of 2018; all they'd need is approval for the device.

    They are close, and even if they only launch with minoxidil, I'd welcome the opportunity to have a well-researched dermarolling protocol performed by a professional, as impreciseness is the reason I don't currently do it.
     
    #4 occulus, Aug 1, 2017
    Last edited: Aug 1, 2017
    Noisette, Newerah, That Guy and 7 others like this.
  5. hairblues

    hairblues Senior Member My Regimen

    Joined:
    Apr 28, 2016
    Messages:
    8,578
    Likes Received:
    8,999
    Dislikes Received:
    296
    My Regimen:
    My Regimen
    My Regimen
  6. Xaser94

    Xaser94 Established Member

    Joined:
    Mar 12, 2016
    Messages:
    282
    Likes Received:
    379
    Dislikes Received:
    4
    Wow noisette this is great! Good job :). I wonder if the hold up for samumed is they are tryng to do a joint 3rd phase with follica. I know there was one article that said they'll be doing naother phase 2, but its been quiet since then.
     
    Noisette, Newerah and NewUser like this.
  7. jo-achim

    jo-achim Established Member

    Joined:
    Nov 13, 2015
    Messages:
    235
    Likes Received:
    257
    Dislikes Received:
    45
    noisette delivers again, boom
     
  8. Xaser94

    Xaser94 Established Member

    Joined:
    Mar 12, 2016
    Messages:
    282
    Likes Received:
    379
    Dislikes Received:
    4
    Its unfortunate as of their most recent webcast in June, they have not started their pivotal trial. We need something to hold us over. I hope brotzu comes out soon.
     
    tomJ and Newerah like this.
  9. NewUser

    NewUser Established Member

    Joined:
    Dec 2, 2015
    Messages:
    324
    Likes Received:
    99
    Dislikes Received:
    12
    Wow that's a lot of new info. Merci Noisette!
     
    Noisette and Newerah like this.
  10. mdmnota

    mdmnota Established Member My Regimen

    Joined:
    Dec 20, 2016
    Messages:
    149
    Likes Received:
    123
    Dislikes Received:
    12
    My Regimen:
    My Regimen
    My Regimen
    How Long are they fucking developing this? Ten years? What a joke haha
     
    br1 and Christian Miller like this.
  11. MrV88

    MrV88 Established Member My Regimen

    Joined:
    Jun 25, 2017
    Messages:
    320
    Likes Received:
    255
    Dislikes Received:
    37
    My Regimen:
    My Regimen
    My Regimen
    Noisette, god of information!
     
  12. Agent

    Agent Established Member My Regimen

    Joined:
    Jan 11, 2017
    Messages:
    104
    Likes Received:
    104
    Dislikes Received:
    3
    My Regimen:
    My Regimen
    My Regimen
    @Noisette, thank you for yet another great post.
     
    Noisette and Christian Miller like this.
  13. That Guy

    That Guy Senior Member My Regimen

    Joined:
    Jul 25, 2016
    Messages:
    1,860
    Likes Received:
    3,559
    Dislikes Received:
    209
    My Regimen:
    My Regimen
    My Regimen
    black-fuckin-a-men-men-s-t-shirt.jpg

    Guess that gives us an answer about diffuse thinners

    Earlier today, on a blog, I was literally saying to someone that "the devil is in the details" with this kind of thing, so I agree.

    Hahaha how sad. They thoroughly researched something before making the move to bringing it to market — idiots!
     
  14. Newerah

    Joined:
    Jul 13, 2017
    Messages:
    81
    Likes Received:
    32
    Dislikes Received:
    25
    My Regimen:
    My Regimen
    My Regimen
    They are close, very close!
     
    Noisette likes this.
  15. thomps1523

    thomps1523 Established Member

    Joined:
    Dec 27, 2007
    Messages:
    303
    Likes Received:
    155
    Dislikes Received:
    25
    So I've got a question if minoxidil is the compound.. I've read that allowing minoxidil to go systematic is extremely hard on your joints among other things. Isn't this jesting that the compound will be in applied immediately after an area is piturbed? Obviously we don't know the degree of piturbation, but isbt it likely possible that applying immediately after may enable it to go systematic? Maybe I'm way off base, but I want to throw it out there for anyone that can answer.
     
    tomJ likes this.
  16. Newerah

    Joined:
    Jul 13, 2017
    Messages:
    81
    Likes Received:
    32
    Dislikes Received:
    25
    My Regimen:
    My Regimen
    My Regimen
    That's true more than 10 years of research...!
     
    br1 likes this.
  17. H

    H Established Member

    Joined:
    Mar 20, 2016
    Messages:
    407
    Likes Received:
    230
    Dislikes Received:
    20
    Wait what answer is that?
     
  18. Christian Miller

    Christian Miller Established Member My Regimen

    Joined:
    Jul 25, 2017
    Messages:
    232
    Likes Received:
    129
    Dislikes Received:
    176
    My Regimen:
    My Regimen
    My Regimen
    In the Indian protocol, minoxidil was applied the next day after dermaneedling. Not right after!
     
    tomJ and br1 like this.
  19. hanginginthewire

    hanginginthewire Established Member

    Joined:
    Apr 14, 2016
    Messages:
    479
    Likes Received:
    464
    Dislikes Received:
    25
    The quoted blurb would indicate they've factored in a way to treat diffuse patients. The "guide comb" attachment would allow you to avoid damaging the native hair.

    In my situation, I can't see it but who knows? I have "too much" (diseased, sickly, minaturizing) hair. ☹️
     
  20. cocona

    Joined:
    Mar 4, 2017
    Messages:
    26
    Likes Received:
    28
    Dislikes Received:
    1
    My Regimen:
    My Regimen
    My Regimen
    I am down with this super fancy dermastamp. Idc if it only advances my hairline by 1/8th inch I'll take it.

    That being said I do have high hopes for this and increasing density.
    :D
     

Share This Page